KIYAN PHARMA Co., Ltd.
Global Healthcare Starting with 5-ALA
KIYAN PHARMA Co., Ltd. contributes to the health of people and animals in various fields such as contract manufacturing of pharmaceutical APIs and intermediates, health foods and cosmetics using 5-aminolevulinic acid (5-ALA), animal health, livestock, aquaculture, and agriculture.
With unique fermentation technology using photosynthetic bacteria, the world’s only factory capable of mass-producing 5-ALA contributes to global health promotion with innovative products and technologies from Japan.
Tokyo Head Office
Fukuroi Plant
Contributing to Global Healthcare with 5-ALA
KIYAN PHARMA Fukuroi Plant advances the production of raw materials for various uses of 5-ALA and the contract manufacturing of other pharmaceutical APIs and intermediates.
Executive Introduction
Chairman of the Board
Hiroyoshi Hata
President
Hiroyuki Ishikawa
Executive Vice President
Shin Mukai
Director CFO
Sozo Imamura
Director
Makoto Tanaka
Director
Kazunari Otsuka
Auditor
Kozo Koseki
Kozo Koseki
Company History
KIYAN PHARMA Co., Ltd. (formerly Neopharma Japan Co., Ltd.) was established in May 2016. In October of the same year, it acquired the Fukuroi Plant from API Corporation, gaining the capacity and facilities for mass production of 5-aminolevulinic acid (5-ALA). This initiative reduced production costs and established a foundation for expansion into various fields such as pharmaceuticals, food, cosmetics, feed, and fertilizers.
March 1971
KIYAN PHARMA’s Fukuroi Plant was established by Roche Japan Co., Ltd. as the world’s largest manufacturing base for vitamin B2 raw material.
May 2016
KIYAN PHARMA Co., Ltd. (formerly Neopharma Japan Co., Ltd.) was established.
October 2016
KIYAN PHARMA acquired the Fukuroi Plant from API Corporation, enabling mass production of 5-aminolevulinic acid (5-ALA).
April 2018
Launch of “Mitocon Power” feed for livestock and poultry.
October 2018
Launch of the original skincare brand “ALAVITA” series.
February 2019
Launch of “EneALA” supplements for dogs and cats with 5-ALA for veterinary use.
September 2019
Launch of “AQUALA” mixed feed for aquaculture.
April 2020
Launch of “ARABIC PK” fertilizer containing 5-ALA.
December 2020
Launch of “Mitocon Power Liquid” mixed feed containing photosynthetic bacteria culture for livestock and poultry.
April 2021
Launch of “5-ALA 50mg” supplements containing 5-aminolevulinic acid phosphate (5-ALA).
August 2022
5-ALA obtained the “Informed Ingredient Certification” from the anti-doping certification program.
November 2022
Launch of “WIZALA” supplements for puppies and kittens.
March 2023
Launch of new supplements “ALAVITAL” containing 5-aminolevulinic acid.
March 2023
The 5-ALA certification mark was registered as a trademark.
May 2023
Launch of “WIZALA” supplements for adult dogs and cats.
July 2023
KIYAN PHARMA changed its executive structure, and Hiroyoshi Hata became Chairman of the Board.
January 2024
Neopharma Japan Co., Ltd. changed its name to KIYAN PHARMA Co., Ltd.
Neopharma Japan Co., Ltd. changed its name to KIYAN PHARMA Co., Ltd.
Corporate Information Overview
KIYAN PHARMA Co., Ltd. advances the development of new drugs using the natural amino acid 5-ALA.
5-ALA through continuous innovation and delivering innovative healthcare products to bring health and a prosperous life.
Based on years of research and scientific knowledge of 5-ALA, contributing to global healthcare as a leading company handling 5-ALA.
Aiming for our products and services to become indispensable in daily life and to support the foundation of people’s health.
Manufacturing 5-ALA for various applications and expanding the production of pharmaceutical APIs and intermediates.
Providing the latest official information promptly. Posting important notices for all stakeholders.